Signed Determination - INOtherapy.pdf

This is a Decision for Sole Source Awards document from the Department of Veterans Affairs (VA) for a procurement under $350,000. The Rocky Mountain Regional VA Medical Center Respirator requires Inhaled Nitric Oxide (INO) services from INO Therapeutics LLC, the sole manufacturer and provider of this specialized pharmaceutical gas. The requirement covers a base year with four one-year options, with an estimated cost that is redacted in the document. The contracting activity is the VA Network Contracting Office 19 in Greenwood Village, Colorado, and the ordering activity is the Rocky Mountain Regional VAMC in Aurora, Colorado.

The INO service delivers hourly inhaled nitric oxide gas to critically ill patients to reduce pulmonary hypertension through vasodilation and treat acute respiratory distress syndrome (ARDS). INO Therapeutics' product offers targeted pulmonary vasodilation that improves oxygenation by directing blood flow to healthier lung areas while maintaining minimal systemic effects, unlike systemic vasodilators. The market research included searches of the Small Business Administration, GSA, FPDS, and SAM databases, which identified only INO Therapeutics LLC as a vendor. A sources sought notice posted on 10/29/2025 received one response from BHPE (SDVOSB). The current FSS contract V797D-60737 expires February 28, 2026, with the program need date of May 26, 2026. Prior awards for similar INO services to Eastern Colorado, Salt Lake City, and Oklahoma City VA Health Care Systems were also awarded to INO Therapeutics LLC as the sole provider.